Abstract: Objective To evaluate the efficacy and safety of bedaquiline (BDQ)in patients with drug resistant pulmonary tuberculosis (DR-PTB)and to provide guidance for clinical rational and safe drug use. Methods We retrospectively reviewed 44 DR-TB patients (including multi-drug resistant pulmonary tuberculosis, MDR-PTB and extensively-drug-resistant TB (XDR-TB) treated with bedaquiline-containing regimen between January 2020 and August 2020 in the Third People's Hospital of Shenzhen. Results The conversion rate of acid-fast bacilli smear was 97.4%(38/39) and the culture conversion rates was 92.9%(26/28) at 24 weeks. There were 49 adverse events in total, including 18 cases of prolonged QTc interval (36.7%) and 10 cases of liver toxicity (20.4%). Among the 18 QTc prolonged adverse events, 3 were clearly related to bedaquiline, accounting for 6.1% of the total adverse events. Treatment was halted in four patients because of prolonged corrected QTc interval, one of which was associated with a single factor of bedaquiline. Conclusion Bedaquiline-containing regimen was effective and safe for patients with pulmonary DR-TB. But it was still necessary to closely monitor adverse reactions, especially the occurrence of prolonged QTc interval.

Key words: Pulmonary tuberculosis, Drug-resistant tuberculosis, Bedaquiline, Retrospective studies, Efficacy